- Home
- CGAU vs BHVN Comparison
CGAU vs BHVN Comparison
Compare CGAU & BHVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGAU
- BHVN
- Stock Information
- Founded
- CGAU 2002
- BHVN 2013
- Country
- CGAU Canada
- BHVN United States
- Employees
- CGAU N/A
- BHVN 256
- Industry
- CGAU Precious Metals
- BHVN Biotechnology: Pharmaceutical Preparations
- Sector
- CGAU Basic Materials
- BHVN Health Care
- Exchange
- CGAU Nasdaq
- BHVN Nasdaq
- Market Cap
- CGAU 1.6B
- BHVN 1.7B
- IPO Year
- CGAU N/A
- BHVN 2017
- Fundamental
- Price
- CGAU $11.38
- BHVN $15.81
- Analyst Decision
- CGAU Buy
- BHVN Strong Buy
- Analyst Count
- CGAU 3
- BHVN 14
- Target Price
- CGAU $12.83
- BHVN $49.23
- AVG Volume (30 Days)
- CGAU 2.4M
- BHVN 2.5M
- Earning Date
- CGAU 10-28-2025
- BHVN 11-11-2025
- Dividend Yield
- CGAU 1.76%
- BHVN N/A
- EPS Growth
- CGAU N/A
- BHVN N/A
- EPS
- CGAU 0.33
- BHVN N/A
- Revenue
- CGAU $1,214,156,000.00
- BHVN N/A
- Revenue This Year
- CGAU $5.72
- BHVN N/A
- Revenue Next Year
- CGAU $9.19
- BHVN $2,195.07
- P/E Ratio
- CGAU $30.67
- BHVN N/A
- Revenue Growth
- CGAU N/A
- BHVN N/A
- 52 Week Low
- CGAU $5.41
- BHVN $12.79
- 52 Week High
- CGAU $11.58
- BHVN $55.70
- Technical
- Relative Strength Index (RSI)
- CGAU 89.35
- BHVN 57.88
- Support Level
- CGAU $10.21
- BHVN $14.32
- Resistance Level
- CGAU $11.58
- BHVN $15.33
- Average True Range (ATR)
- CGAU 0.34
- BHVN 0.90
- MACD
- CGAU 0.14
- BHVN 0.16
- Stochastic Oscillator
- CGAU 92.21
- BHVN 84.86
About CGAU Centerra Gold Inc.
Centerra Gold Inc a gold mining and exploration company engaged in the operation, exploration, development, and acquisition of gold properties in Asia, North America, and other markets world-wide. The company reportable operating segments are Oksut; Mount; and Milligan Molybdenum. It derives maximum revenue from Oksut segment. Geographically, it operates in Turkey, United States, Canada and Other.
About BHVN Biohaven Ltd.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.